Abstract
There are numerous ways by which the middle cerebral artery (MCA) can be occluded in order to provoke a focal cerebral ischemia (either of a permanent nature or with reperfusion) in experimental animals: electrocoagulation, microvascular clips, sutures or intraluminal thread models – that include both an extravascular and endovascular approach, respectively –, injection of a foreign or autologous thrombus, microemboli, the production of an in situ clot formation by using rose-Bengal, or even the placement of a balloon catheter around, or directly into, the MCA per se. Some of these models were specifically designed to establish a reproducible volume of ischemic damage in which various pharmacological agents could be screened for their efficacy as “neuroprotector agents” in as small a number of animals as possible without losing statistical pertinence. None of the widely tested “neuroprotector agents” employed in any of the above models of focal cerebral ischemia has found a place in the clinical treatment of stroke. This finding is perhaps not surprising, as stroke in humans is rarely confined to one anatomical brain region, is often associated with other underlying pathologies, such as hypertension or diabetes, and where the location of the ischemic damage may be more important, in terms of neurological deficits, than the actual volume of the infarct itself. In this chapter, we describe two experimental models of stroke which, we believe, represent more closely the clinical condition of a cerebrovascular accident. The first model, one of thromboembolic cerebral ischemia in the rat, was established more than 20 years ago by Longa et al. (see 12). The procedure involves the injection of an autologous blood clot into the internal carotid artery (ICA) of the anesthetized rat which then, due to the size of the clot, becomes lodged at the origin of the MCA. However, there are a number of disadvantages associated with this model including: a high mortality rate after periods of ischemia >45 min; secondary ischemic foci following disruption of the clot (if treated by thrombolysis); variability in the final location of the clot and irregularity of the final infarct volume as a consequence of the degree of reduction in cerebral blood flow (CBF) to the brain region in question. Nonetheless, these “so-called” disadvantages are indeed encountered in humans following stroke. The second method is more recent and also involves the establishment of a thromboembolic stroke, this time in the anesthetized mouse. This new experimental model was developed by Orset et al. (see 13). To induce a focal cerebral ischemia, a micropipette is used to deliver a given volume of thrombin directly into the lumen of the exposed MCA, thereby obstructing the blood supply to the MCA territory as can be determined by Laser Doppler sonography. Given the limited vascular supply in this lissencephalic species, the infarcts are highly reproducible and there is no mortality associated with the surgical intervention. A craniotomy is, however, necessary for this procedure which, in turn, may reduce the additional deleterious consequences of raised intracranial pressure (ICP) normally associated with cerebral ischemia and thus limits the final infarct volume due to the occlusion. The experimental procedures for both the techniques as well as their advantages and disadvantages are described in the following pages.
Key words
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hennerici M, Mahagne M-H (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute stroke Study (ECASS). JAMA 274:1017–1025
Hacke W, Bluhmki E, Steiner T, Tatlisumak T, Mahagne MH, Sacchetti ML, Meier D (1998) Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set: post hoc analysis of ECASS I. Stroke 29:2073–2075
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581–1587
Zhang Z, Chopp M, Zhang RL, Goussev A (1997) A mouse model of embolic focal cerebral ischemia. J Cereb Blood Flow Metab 17:1081–1088
Busch E, Krüger K, Hossmann K-A (1997) Improved model of thromboembolic stroke and rt-PA induced reperfusion in the rat. Brain Res 778:16–24
Lapchak PA, Chapman DF, Zivin JA (2000) Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 31:3034–3039
Yamaguchi S, Yamakawa T, Niimi H (2000) Microcirculatory responses to repeated embolism-reperfusion in cerebral microvessels of cat: a fluorescence videomicroscopic study. Clin Hemorheol Microcirc 23:313–319
Kito G, Nishimura A, Susumu T, Nagata R, Kuge Y, Yokota C, Minematsu K (2001) Experimental thromboembolic stroke in cynomolgus monkey. J Neurosci Methods 105:45–53
Watanabe O, Bremer AM, West CR (1977) Experimental regional cerebral ischemia in the middle cerebral artery territory in primates. Part 1: angio-anatomy and description of an experimental model with selective embolization of the internal carotid artery bifurcation. Stroke 8:61–70
Orset C, Macrez R, Young AR, Panthou D, Angles-Cano E, Maubert E, Agin V, Vivien D (2007) Mouse model of in situ thromboembolic stroke and reperfusion. Stroke 38:2771–2778
De Keyser J, Sulter G, Luiten PG (1999) Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci 22:535–540
Longa EZ, Weinstein PR, Carlson S, Cummins R (1989) Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20:84–91
Orset C, Macrez R, Young AR, Panthou D, Angles-Cano E, Maubert E, Agin V, Vivien D (2007) Mouse model of in situ thromboembolic stroke and reperfusion. Stroke 38:2771–2778
Zhang Z, Zhang RL, Jiang Q, Raman SBK, Cantwell L, Chopp M (1997) A new rat model of thrombotic focal cerebral ischemia. J Cereb Blood Flow Metab 17:123–135
Zhang RL, Chopp M, Zhang ZG, Jiang Q, Ewing JR (1997) A rat model of focal embolic cerebral ischemia. Brain Res 766:83–92
Meng W, Wang XY, Asahi M, Kano T, Asahi K, Ackerman RH, Lo EH (1999) Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats. J Cereb Blood Flow Metab 19:1316–1321
Asahi M, Asahi K, Wang XY, Lo EH (2000) Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J Cereb Blood Flow Metab 20:452–457
Wang XK, Xu L, Wang H, Grzanna R, Zhan YT, Knabb RM, Luettgen JA, Bozarth TA, Galemmo RA, Wong PC, Bernard R, Vargas H, Chopp M, Friedman SM, Feuerstein GZ (2003) Inhibition of factor Xa reduces ischemic brain damage after thromboembolic stroke in rats. Stroke 34:468–474
Kelly MA, Shuaib A, Todd KG (2006) Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis. Exp Neurol 200:38–49
Wang-Fischer Ye (2009) Manual of stroke models in rats. CRC Press, London
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Humana Press
About this protocol
Cite this protocol
Orset, C., Haelewyn, B., Vivien, K., Vivien, D., Young, A.R. (2010). Rodent Models of Thromboembolic Stroke. In: Dirnagl, U. (eds) Rodent Models of Stroke. Neuromethods, vol 47. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-750-1_6
Download citation
DOI: https://doi.org/10.1007/978-1-60761-750-1_6
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-749-5
Online ISBN: 978-1-60761-750-1
eBook Packages: Springer Protocols